Loading stock data…
BiomX Inc. (PHGE)
$0.36-0.04 (-9.25%)
Market ClosedLast close Jun 29
BiomX Inc., a holding company, focuses on defense, security, and critical infrastructure technologies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BiomX Inc. in the Industrials sector is trading at $0.36 with a market capitalization of $4M. The stock is currently near its 52-week low of $0.30, remaining 92.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.30M↑ | -$7.20M↑ | -$8.54M↓ | -$7.43M↑ | -$7.76M |
| Net Income | -$19.14M↓ | -$13.34M↓ | -$9.17M↓ | -$6.04M↑ | -$7.66M |
Peer Comparison
Fundamentals
BiomX Inc., a holding company, focuses on defense, security, and critical infrastructure technologies. The company's portfolio targets various niches, such as counter-drone systems, AI-enabled command-and-control, perimeter and border security, wide-...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
5412.03%
Volume
Today's trading volume
13.11M
Recent News
BiomX announces $3M private placement
BiomX (PHGE) entered into definitive agreements in connection with a private investment in public equity financing for expected gross proceeds of approximately $3M, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. In the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of $1,000 per share, together with warrants w
All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy
BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the
Top Midday Decliners
Meihua International Medical Technologies (MHUA) shares plunged 43% after the company reported late
BiomX Inc (PHGE) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
BiomX Inc (PHGE) progresses in clinical trials for BX004 and BX011, despite facing financial constraints and a temporary FDA hold on US trials.